Expert Panel Approves Post-Marketing Surveillance Study of Eculizumab (Soliris) by AstraZeneca in India

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-07-06 09:30 GMT | Update On 2025-07-06 09:30 GMT

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to AstraZeneca Pharma India Ltd to conduct a Post Marketing Surveillance (PMS) study for its monoclonal antibody drug Eculizumab (Soliris) in India.

As per the official minutes, “The firm presented the proposal to conduct the Post Marketing Surveillance Study (PMS) in India for Eculizumab concentrate for solution for infusion 300 mg (10mg/ml) (Soliris) titled ‘A Prospective, Observational, Multicenter, Post Marketing Surveillance Study to assess safety of Eculizumab in Indian patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)’ vide study code D7414R00002 Version 1.0 dated 09.04.2025 as per the condition of Marketing Authorization approval.”

Following detailed deliberation during the SEC (Hematology) meeting held on 28th May 2025, the committee stated:

“After detailed deliberation, the committee recommended for grant of permission to conduct the Post Marketing Surveillance Study (PMS) as per the protocol presented by the firm.”

Eculizumab is a humanized monoclonal antibody that targets complement protein C5. By binding to this protein, it prevents activation of the terminal complement cascade, a critical mechanism in several rare and severe autoimmune diseases. The drug is approved for treating Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS).

The PMS study will assess the real-world safety of Eculizumab in Indian patients diagnosed with PNH, as part of the firm’s post-marketing obligations under its Marketing Authorization.

Also Read: Sun Pharma Gets CDSCO Panel Go-Ahead to Manufacture, Market Relugolix, Estradiol, Norethindrone Acetate FDC

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Expert Panel Approves Post-Marketing Surveillance Study of Eculizumab (Soliris) by AstraZeneca in India

Similar News

Govt Panel Proposes Braille Cards, Voice-Enabled QR Codes on Medicine Packs to Aid Visually Impaired

Pfizer's Abrocitinib Phase III Data Accepted by CDSCO Expert Committee

Govt Panel Makes This Approval Mandatory For New Drug Licenses

CDSCO Panel Asks Glenmark To Justify BE Waiver for FDC Inhalation Suspension With Scientific Evidence

Sun Pharma Gets SEC Nod to Begin Phase III Trial of Cough Drug Gefapixant

Pfizer Told To Conduct Phase IV Trial of Abrocitinib in Indian Adolescents with Atopic Dermatitis

Submit Full Adverse Event Data from Lenvatinib Phase IV Liver Cancer Trial: CDSCO Panel To Eisai Pharma